Is BEAM or CADL more undervalued in 2026?

CirclFi compares Beam Therapeutics Inc. (BEAM) and Candel Therapeutics, Inc. (CADL) using 13 institutional-grade valuation models. BEAM has a Quality of Company score of 6.4/10 while CADL scores 4.4/10.

Which is a better buy — BEAM or CADL?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do BEAM and CADL valuations compare?

BEAM at $32.93 and CADL at $8.30 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

BEAM vs CADL Valuation Comparison 2026 — Intrinsic Value Analysis

BEAM

Biological Products, (No Diagnostic Substances)

Beam Therapeutics Inc.

Quality

6.4

out of 10

Value Trap

SAFE

Price

$32.93

Last close

Models

12/13

Active

CADL

Biological Products, (No Diagnostic Substances)

Candel Therapeutics, Inc.

Quality

4.4

out of 10

Value Trap

LOW

Price

$8.30

Last close

Models

8/13

Active

Model-by-Model Comparison

Model	Type	BEAM Fair Value	BEAM Upside	CADL Fair Value	CADL Upside
Bayesian DCF	Intrinsic	$8.58	-74.0%	$3.24	-60.9%
Earnings Power Value	Intrinsic	$15.21	-43.9%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$10.26	-68.8%	$2.44	-70.6%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for BEAM vs CADL — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

BEAM vs CADL — Which Stock Is More Undervalued?

BEAM scores higher with a 6.4/10 quality rating vs CADL's 4.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Beam Therapeutics Inc. (BEAM) and Candel Therapeutics, Inc. (CADL) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

BEAM currently trades at $32.93 with a QOC of 6.4/10, while CADL trades at $8.30 with a QOC of 4.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).